% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{vanGroen:3797,
author = {van Groen, T. and Kadish, I. and Wiesehan, K. and Funke, S.
A. and Willbold, D.},
title = {{I}n vitro and in vivo staining characteristics of small,
fluorescent, {A}ß42 binding {D}-enantiomeric peptides in
transgenic {AD} mouse models},
journal = {ChemMedChem},
volume = {4},
issn = {1860-7179},
address = {Weinheim [u.a.]},
publisher = {Wiley-VCH},
reportid = {PreJuSER-3797},
pages = {276 - 282},
year = {2009},
note = {This work was supported by a grant from the
Volkswagen-Stiftung to D.W. (1/82 649).},
abstract = {One of the characteristic pathological hallmarks of
Alzheimer's disease (AD) are neuritic plaques that consist
of amyloid peptide (Abeta). To improve diagnosis and
treatment evaluation, neuroimaging tools that make use of
Abeta-binding ligands to visualise amyloid plaques are being
developed. We investigate the in vitro and in vivo
characteristics of a series of three D-enantiomeric peptides
(D1-D3) that were developed to specifically bind amyloid
beta1-42 (Abeta42) in the brains of transgenic AD-model
mice. We stained brain sections of the mice, injected and
infused the mice with these small D-peptides, and examined
their staining of Abeta42 in the brain. The experiments
demonstrate that the D-peptides label all plaques that
contain Abeta42 in the brain. In contrast, diffuse amyloid
beta deposits (which do not contain Abeta42) are not stained
by any of the D-peptides. The in vivo and in vitro studies
demonstrate that the D-peptides label all Abeta42 in the
brain, and none of the D-peptides causes inflammation or is
taken up by astrocytes or microglia. Furthermore, long-term
infusion of the peptides does not cause inflammation.
Together, this demonstrates that these D-peptides might be
suitable for use as molecular probes to measure Abeta plaque
load in the living brain for early diagnosis of Alzheimer's
disease, or to monitor Abeta42 plaque load during disease
progression or during treatment.},
keywords = {Alzheimer Disease: metabolism / Amino Acid Sequence /
Amyloid beta-Peptides: chemistry / Amyloid beta-Peptides:
metabolism / Animals / Disease Models, Animal / Fluorescent
Dyes: chemistry / Mice / Mice, Transgenic / Peptide
Fragments: chemistry / Peptide Fragments: metabolism /
Peptides: metabolism / Protein Binding / Stereoisomerism /
Amyloid beta-Peptides (NLM Chemicals) / Fluorescent Dyes
(NLM Chemicals) / Peptide Fragments (NLM Chemicals) /
Peptides (NLM Chemicals) / amyloid beta-protein (1-42) (NLM
Chemicals) / J (WoSType)},
cin = {ISB-3 / JARA-HPC},
ddc = {540},
cid = {I:(DE-Juel1)VDB942 / $I:(DE-82)080012_20140620$},
pnm = {Funktion und Dysfunktion des Nervensystems},
pid = {G:(DE-Juel1)FUEK409},
shelfmark = {Chemistry, Medicinal / Pharmacology $\&$ Pharmacy},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:19072935},
UT = {WOS:000263803200016},
doi = {10.1002/cmdc.200800289},
url = {https://juser.fz-juelich.de/record/3797},
}